| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Cytochrome P450 2C9 |
|---|
| Ligand | BDBM50033373 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_1434291 (CHEMBL3385836) |
|---|
| IC50 | >10000±n/a nM |
|---|
| Citation |  Xia, G; Chen, W; Zhang, J; Shao, J; Zhang, Y; Huang, W; Zhang, L; Qi, W; Sun, X; Li, B; Xiang, Z; Ma, C; Xu, J; Deng, H; Li, Y; Li, P; Miao, H; Han, J; Liu, Y; Shen, J; Yu, Y A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. J Med Chem57:9889-900 (2014) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Cytochrome P450 2C9 |
|---|
| Name: | Cytochrome P450 2C9 |
|---|
| Synonyms: | (R)-limonene 6-monooxygenase | (S)-limonene 6-monooxygenase | CP2C9_HUMAN | CYP2C10 | CYP2C9 | CYPIIC9 | Cytochrome P450 2C9 (CYP2C9 ) | Cytochrome P450 2C9 (CYP2C9) | P-450MP | P450 MP-4/MP-8 | P450 PB-1 | S-mephenytoin 4-hydroxylase |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 55636.33 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P11712 |
|---|
| Residue: | 490 |
|---|
| Sequence: | MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV
|
|
|
|---|
| BDBM50033373 |
|---|
| n/a |
|---|
| Name | BDBM50033373 |
|---|
| Synonyms: | CHEMBL3357641 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C24H24ClF2N5O3 |
|---|
| Mol. Mass. | 503.929 |
|---|
| SMILES | CN(C)C\C=C(/F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 |r| |
|---|
| Structure | 
|
|---|
Search and Browse
